Innovative Molecular Target and Therapeutic Approaches in Nonalcoholic Fatty Liver Disease/Nonalcoholic Steatohepatitis (NAFLD/NASH) 2.0

被引：1
|
作者：
Vairetti, Mariapia [1 ]
Colucci, Giuseppe [2 ]
Ferrigno, Andrea [1 ]
机构：
[1] Univ Pavia, Dept Internal Med & Therapeut, I-27100 Pavia, Italy
[2] Univ Milan, Fdn IRCCS Ca Granda Osped Maggiore Policlin, Dept Pathophysiol & Transplantat, Div Gastroenterol & Hepatol, I-20122 Milan, Italy
来源：
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2022年 / 23卷 / 14期
关键词：
STEATOSIS; MODEL; DIET; ACID;
D O I：
10.3390/ijms23147894
中图分类号：
Q5 [生物化学]; Q7 [分子生物学];
学科分类号：
071010 ; 081704 ;
摘要：
引用
收藏
页数：4
相关论文
共 50 条
  • [21] MODELING NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NONALCOHOLIC STEATOHEPATITIS (NASH) WITH HUMAN MULTI-CELL-LINEAGE LIVER ORGANOIDS
    Zhang, Wenjun
    Park, Yujin
    Thadasina, Deepthi
    Isidan, Abdulkadir
    Bolujo, Ifeoluwa
    Wilmes, Danielle M.
    Farag, Kristine
    Lopez, Kevin
    Cross-Najafi, Arthur A.
    Li, Ping
    Kyritsi, Konstantina
    Kennedy, Lindsey
    Glaser, Shannon S.
    Francis, Heather L.
    Alpini, Gianfranco
    Ekser, Burcin
    HEPATOLOGY, 2022, 76 : S699 - S700
  • [22] DIAGNOSING NONALCOHOLIC STEATOHEPATITIS (NASH) AMONG PATIENTS WITH NONALCOHOLIC FATTY LIVER DISEASE (NAFLD): FEQUENCY AND PREDICTORS OF NAFLD ACTIVITY SCORE MEASUREMENT
    Katz, J.
    Heinz, S.
    DiBonaventura, M.
    VALUE IN HEALTH, 2017, 20 (05) : A180 - A180
  • [23] EMPHASIZING DIVERSITY IN NONALCOHOLIC STEATOHEPATITIS (NASH) STUDIES: CHARACTERIZATION OF A NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) SCREENING DATABASE.
    Paglialunga, S.
    Jaycox, S.
    Kar, S.
    CLINICAL PHARMACOLOGY & THERAPEUTICS, 2020, 107 : S39 - S39
  • [24] Effect of Metformin on Ballooning Degeneration in Nonalcoholic Steatohepatitis (NASH): When to Use Metformin in Nonalcoholic Fatty Liver Disease (NAFLD)
    Doycheva, Iliana
    Loomba, Rohit
    ADVANCES IN THERAPY, 2014, 31 (01) : 30 - 43
  • [25] Effect of Metformin on Ballooning Degeneration in Nonalcoholic Steatohepatitis (NASH): When to Use Metformin in Nonalcoholic Fatty Liver Disease (NAFLD)
    Iliana Doycheva
    Rohit Loomba
    Advances in Therapy, 2014, 31 : 30 - 43
  • [26] THE DIPEPTIDYL PEPTIDASE 4 INHIBITOR LINAGLIPTIN IS AN EFFECTIVE THERAPEUTIC FOR METABOLIC LIVER DISEASE IN SEVERAL RODENT MODELS OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NONALCOHOLIC STEATOHEPATITIS (NASH)
    Klein, Thomas
    Mark, Michael
    Schuppan, Detlef
    HEPATOLOGY, 2011, 54 : 369A - 369A
  • [27] Longitudinal Analyses of Comorbidities and Healthcare Costs Among Nonalcoholic Fatty Liver Disease (NAFLD)/Nonalcoholic Steatohepatitis (NASH) Patients with Advanced Liver Disease
    Harrison, Stephen A.
    Kachru, Nandita
    Parker, Emily
    Korrer, Stephanie
    Loomba, Rohit
    HEPATOLOGY, 2018, 68 : 572A - 573A
  • [28] Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    不详
    CLINICAL GASTROENTEROLOGY AND HEPATOLOGY, 2020, 18 (05)
  • [29] PATHOGENETIC ANALYSIS OF NONALCOHOLIC FATTY LIVER DISEASE (NAFLD) AND NONALCOHOLIC STEATOHEPATITIS (NASH) WITH MULTI-CELL-LINEAGE HUMAN LIVER ORGANOIDS
    Zhang, Wenjun
    Park, Yujin
    Thadasina, Deepthi
    Thi Minh Uyen Le
    Li, Ping
    Ekser, Burcin
    HEPATOLOGY, 2023, 78 : S1121 - S1122
  • [30] Prevalence and predictors of de novo nonalcoholic fatty liver disease (NAFLD)/nonalcoholic steatohepatitis (NASH) after orthotopic liver transplantation (OLT)
    Seo, Suk
    Maganti, Kalyani
    Khehra, Manjit
    Ramsamooj, Rajendra
    Tsodikov, Alexander
    Torok, Natalie
    GASTROENTEROLOGY, 2006, 130 (04) : A789 - A789
12345